Friday - May 29, 2026
Bepirovirsen Achieves Unprecedented Functional Cure Rates With Potential to Redefine Treatment for Chronic Hepatitis B
May 29, 2026
LONDON, England, May 29 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

* Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity compared to 0% with standard of care only/1

* 49% of bepirov . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products